COMPASS Pathways plc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CMPS Nasdaq 2834 compasspathways.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for COMPASS Pathways plc

Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 - Sep 16th, 2026 4:30 am
COMPASS Pathways (CMPS) Stock May Be Fully Priced On Phase 3 Data - Sep 16th, 2026 12:11 am
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026 - Sep 15th, 2026 4:30 am
Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360 - Sep 11th, 2026 2:10 pm
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training - Sep 10th, 2026 6:00 am
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training - Sep 10th, 2026 4:35 am
Compass Pathways to Participate in Investor Conferences the Week of September 14th - Sep 10th, 2026 4:30 am
Compass Pathways stock rises as 52-week data show lasting depression relief - Sep 9th, 2026 10:19 am
CMPS Stock Defies Market Selloff After Compass Pathways Psilocybin Trial Success Pointing To 2027 Launch - Sep 9th, 2026 8:06 am
Compass Pathways reports 52-week Phase 3 COMP005 results for COMP360 - Sep 9th, 2026 6:48 am
Wall Street slips for a third straight day as oil and yields climb - Sep 9th, 2026 5:56 am
Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year - Sep 9th, 2026 4:30 am
CMPS Stock Rallies On Launch-Prep Push Ahead Of FDA Psychedelics Hearing - Sep 8th, 2026 4:28 pm
Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026 - Sep 8th, 2026 4:30 am
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 3rd, 2026 2:30 pm
Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree - Sep 2nd, 2026 4:30 am
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026 - Sep 1st, 2026 4:30 am
CMPS Stock Clocks 25% Gains In August Ahead Of Application Filing For Drug, FDA Hearing On Psychedelics - Aug 24th, 2026 5:23 pm
Cybin Conference: Helus CEO Eyes Q4 Phase III Depression Data for HLP003 - Aug 14th, 2026 5:04 am